Microsieving diluted suspensions of oxygenated sickle cell anaemia (HbSS) cells on polycarbonate filters shows that piracetam improves the red cell deformability in vitro. In vivo an oral intake of 160 mg/kg/day divided in four doses enhances the HbSS cell deformability as actively as it does in in vitro experiments. The drug is also able partially to restore the impaired deformability of physiologically deoxygenated HbSS cells. These findings are consistent with the results of clinical trials, which show that continuous treatment with piracetam reduces the incidence of vaso-occlusive crises in patients with sickle cell disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1140837 | PMC |
| http://dx.doi.org/10.1136/jcp.40.1.99 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prophylactic vs therapeutic blood transfusions impact on pregnant sickle cell patients.
Pak J Med Sci
January 2025
Khalid Khalil Security Forces Hospital Makkah, Makkah, Saudi Arabia.
Objective: To observe the fetomaternal outcome of therapeutic versus prophylactic blood transfusions in patients with sickle cell disease (SCD) during pregnancy.
Method: This single-center retrospective observational study was conducted on consecutive pregnant women with SCD between January 2018 and December 2020. All the pregnant women with SCD were included in this study.
Non-myeloablative hematopoietic cell transplantation (HCT) is a curative option for individuals with sickle cell disease (SCD). Our traditional goal with this approach has been to achieve a state of mixed donor/recipient chimerism. Recently, we reported an increased risk of hematologic malignancies (HMs) in adults with SCD following graft failure or mixed chimerism.
View Article and Find Full Text PDFSickle Cell Disease: A Potential Cause of Immune Thrombocytopenia.
Cureus
December 2024
Internal Medicine, King Fahad Hospital Hofuf, Hofuf, SAU.
Sickle cell anemia (SCA) is one of the known hemoglobinopathies that result in red blood cell (RBC) destruction, among other complications. There are factors that make SCA an environment for autoimmune disease (AID). They include chronic inflammation, immune-mediated processes involved in SCA complications, and susceptibility to infections.
View Article and Find Full Text PDFProfiles of systemic lupus erythematosus patients with co-existing sickle cell disease: a coincidence or true association?
Reumatologia
December 2024
Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Nigeria.
Introduction: Systemic lupus erythematosus (SLE) and sickle cell disease (SCD) are distinct multisystemic diseases that commonly affect blacks. There are few reports of their co-existence in Western literature and a paucity of reports in Sub-Saharan Africa. Their co-existence is associated with diagnostic delay and treatment dilemmas.
View Article and Find Full Text PDFChallenges of Engaging Primary Care Providers in Specialized Telementoring Education About Sickle Cell Disease for Sickle Cell Specialists: Results from the Sickle Cell Disease Training and Mentoring Program for Primary Care Providers (STAMP) Project ECHO.
AJPM Focus
February 2025
Department of Medicine, University of Alabama, Bermingham, Alabama.
Introduction: Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 100,000 individuals in the U.S. A lack of knowledgeable providers, particularly for adult patients, has led to a significant number of adults without access to high-quality care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!